GlassScriptPhysician profile
Claire W Thomas
NPI 1952746406
$2,681.80
in general payments reported to CMS, 2019-2025
31 companies · $15.03 in 2025
The $15.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $817 · 2021: $269 · 2022: $267 · 2023: $333 · 2024: $13.51 · 2025: $15.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.59 | 2021-2024 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $361.15 | 2019-2021 | |
| Novo Nordisk INC | $227.04 | 2019-2023 | |
| Glaxosmithkline, LLC. | $208.84 | 2019-2022 | |
| Lilly USA, LLC | $186.28 | 2019-2023 | Mounjaro, Trulicity |
| Amgen INC. | $153.42 | 2019-2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $124.46 | 2019-2023 | Farxiga |
| Pfizer INC. | $123.13 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $116.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $96.62 | 2019 | |
| Irhythm Technologies, INC. | $93.64 | 2019 | |
| Allergan, INC. | $60.91 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $53.78 | 2019-2020 | |
| Horizon Therapeutics Plc | $48.05 | 2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $42.38 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.35 | 2019 | |
| Medtronic, INC. | $33.24 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Merck Sharp & Dohme LLC | $32.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.01 | 2019 | |
| Shire North American Group INC | $26.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.37 | 2019 | |
| Upsher-Smith Laboratories LLC | $24.72 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.66 | 2022 | |
| Esperion Therapeutics, INC. | $23.29 | 2022 | |
| Boston Scientific Corporation | $19.84 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2020 | |
| Concordia Pharmaceuticals INC. | $17.06 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.45 | 2023 | Onpattro |
| Sanofi Pasteur INC. | $14.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.